Dr. Marcelyn Ann Lepique, M.D. Obstetrics & Gynecology - Gynecology Medicare: Medicare Enrolled Practice Location: 1311a N Mildred Rd, Cortez, CO 81321 Phone: 970-564-2662 Fax: 970-564-2658 |
Jessica Kaplan, M.D., M.P.H. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1311a N Mildred Rd, Cortez, CO 81321 Phone: 970-565-8556 |
Erin D Schmitt, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1311a N Mildred Rd, Cortez, CO 81321 Phone: 970-565-8665 Fax: 970-564-1134 |
Kimberly Ann Washburn, N.P. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1311a N Mildred Rd, Cortez, CO 81321 Phone: 970-565-8556 Fax: 970-564-1134 |
Dr. Daniel James Bohle, M.D. Obstetrics & Gynecology - Gynecology Medicare: Not Enrolled in Medicare Practice Location: 20 S Market St, Suite 1, Cortez, CO 81321 Phone: 970-565-4291 Fax: 970-565-4419 |
Dr. James E Roukema, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1311a N Mildred Rd, Cortez, CO 81321 Phone: 970-565-8556 |
News Archive
Californian scientists have found that women who become mothers after age 50 are physically and mentally as capable of fulfilling the role of a good mother as women who are much younger.
A new report from the Health Protection Agency shows that around three-quarters of injecting drug users (IDUs) have been homeless at some point. In addition, those who have been homeless have higher levels of injecting risk and associated infections, primarily through the sharing of needles and low standards of hygiene.
The Influenza Specialist Group (ISG) is today warning that high rates of influenza outbreaks have been confirmed in QLD, SA and NSW, but there is still time for most Australians, especially those in at-risk groups, to protect themselves and those around them.
arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).
› Verified 8 days ago